首页> 外文期刊>Biochemical Pharmacology >Selective scavenging of intra-mitochondrial superoxide corrects diclofenac-induced mitochondrial dysfunction and gastric injury: A novel gastroprotective mechanism independent of gastric acid suppression
【24h】

Selective scavenging of intra-mitochondrial superoxide corrects diclofenac-induced mitochondrial dysfunction and gastric injury: A novel gastroprotective mechanism independent of gastric acid suppression

机译:选择性清除线粒体内过氧化物可纠正双氯芬酸诱导的线粒体功能障碍和胃损伤:一种独立于胃酸抑制的新型胃保护机制

获取原文
获取原文并翻译 | 示例
           

摘要

Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used to treat multiple inflammatory diseases and pain but severe gastric mucosal damage is the worst outcome of NSAID-therapy. Here we report that mitoTEMPO, a mitochondrially targeted superoxide (O-2(-)) scavenger protected as well as healed gastric injury induced by diclofenac (DCF), the most commonly used NSAID. Common existing therapy against gastric injury involves suppression of gastric acid secretion by proton pump inhibitors and histamine H-2 receptor antagonists; however, dyspepsia, vitamin B12 deficiency and gastric microfloral dysbalance are the major drawbacks of acid suppression. Interestingly, mitoTEMPO did not inhibit gastric acid secretion but offered gastroprotection by preventing DCF-induced generation of O-2(-) due to mitochondrial respiratory chain failure and by preventing mitochondrial oxidative stress (MOS)-mediated mitopathology. MitoTEMPO even restored DCF-stimulated reduced fatty acid oxidation, mitochondrial depolarization and bioenergetic crisis in gastric mucosa. MitoTEMPO also prevented the activation of mitochondrial pathway of apoptosis and MOS-mediated proinflammatory signaling through NF-kappa B by DCF. Furthermore, mitoTEMPO when administered in rats with preformed gastric lesions expedited the healing of gastric injury and the healed stomach exhibited its normal physiology as evident from gastric acid and pepsin secretions under basal or stimulated conditions. Thus, in contrast to the existing antiulcer drugs, mitochondrially targeted O-2-scavengers like mitoTEMPO may represent a novel class of gastroprotective molecules that does not affect gastric acid secretion and may be used in combination with DCF, keeping its anti-inflammatory action intact, while reducing its gastrodamaging effects. (C) 2016 Elsevier Inc. All rights reserved.
机译:非甾体类抗炎药(NSAIDs)被广泛用于治疗多种炎症性疾病和疼痛,但是严重的胃粘膜损害是NSAID治疗的最坏结果。在这里,我们报告说,线粒体靶向的超氧化物(O-2(-))清除剂mitoTEMPO受双氯芬酸(DCF)(最常用的NSAID)诱导的胃损伤得到了保护和愈合。现有的针对胃损伤的常见疗法包括通过质子泵抑制剂和组胺H-2受体拮抗剂抑制胃酸分泌。但是,消化不良,维生素B12缺乏和胃部菌群失调是抑制酸的主要缺点。有趣的是,mitoTEMPO不会抑制胃酸分泌,而是通过防止DCF诱导的线粒体呼吸链衰竭导致的O-2(-)生成以及通过防止线粒体氧化应激(MOS)介导的线粒体病理学提供胃保护作用。 MitoTEMPO甚至可以恢复DCF刺激的胃粘膜脂肪酸氧化减少,线粒体去极化和生物能危象。 MitoTEMPO还阻止了DCF通过NF-κB激活线粒体凋亡的途径以及MOS介导的促炎信号传导。此外,当在患有预先形成的胃部病变的大鼠中施用mitoTEMPO可以加速胃部损伤的愈合,并且在基础或刺激条件下,从胃酸和胃蛋白酶的分泌可以明显看出,愈合的胃部表现出其正常的生理机能。因此,与现有的抗溃疡药物相比,线粒体靶向的O-2-清除剂(如mitoTEMPO)可能代表一类新型的胃保护分子,它不影响胃酸分泌,可以与DCF组合使用,从而保持其抗炎作用完整,同时减少其对胃的损害。 (C)2016 Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号